Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Francois Nader purchased 36,500 shares of the business’s stock in a transaction dated Thursday, July 21st. The shares were purchased at an average price of $3.72 per share, for a total transaction of $135,780.00. Following the purchase, the director now owns 138,500 shares of the company’s stock, valued at approximately $515,220. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Francois Nader also recently made the following trade(s):
- On Tuesday, July 19th, Francois Nader bought 50,000 shares of Talaris Therapeutics stock. The shares were purchased at an average cost of $3.52 per share, with a total value of $176,000.00.
Talaris Therapeutics Price Performance
Shares of TALS stock opened at $3.92 on Tuesday. Talaris Therapeutics, Inc. has a 12-month low of $2.04 and a 12-month high of $17.48. The business has a 50 day simple moving average of $6.21 and a 200 day simple moving average of $7.83. The firm has a market capitalization of $162.54 million, a price-to-earnings ratio of -2.63 and a beta of 3.77.
Institutional Trading of Talaris Therapeutics
Several institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its position in Talaris Therapeutics by 7.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 24,821 shares of the company’s stock valued at $244,000 after purchasing an additional 1,733 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Talaris Therapeutics by 4.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 52,058 shares of the company’s stock valued at $513,000 after acquiring an additional 2,352 shares during the period. New York State Common Retirement Fund grew its stake in Talaris Therapeutics by 32.5% in the fourth quarter. New York State Common Retirement Fund now owns 10,189 shares of the company’s stock valued at $156,000 after acquiring an additional 2,500 shares during the period. JPMorgan Chase & Co. grew its stake in Talaris Therapeutics by 26.3% in the first quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company’s stock valued at $146,000 after acquiring an additional 3,090 shares during the period. Finally, Amalgamated Bank acquired a new position in shares of Talaris Therapeutics during the first quarter worth about $31,000. Institutional investors and hedge funds own 74.84% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on TALS shares. Morgan Stanley lowered Talaris Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $20.00 to $8.00 in a research note on Tuesday, July 5th. Guggenheim dropped their price objective on Talaris Therapeutics to $23.00 and set a “na” rating on the stock in a report on Monday, May 16th. Finally, SVB Leerink downgraded Talaris Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $21.00 to $7.00 in a research note on Thursday, June 30th.
Talaris Therapeutics Company Profile
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- The Institutions Like The Color Of PPG Industries
- Palantir Stock is Showing Signs of Life
- Taking a Look at Nvidia’s Stock Amidst The Semiconductor Chip Gut
- What Investors Need to Know to Beat the Market
- Alcoa Is Well-Positioned For 2022 and 2023
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.